Ibogaine Interactions

A

  • Amitriptyline - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; consider tapering and discontinuing at least 2 weeks prior

B

  • Bupropion - may increase the risk of seizures in combination; may increase ibogaine blood concentrations; consider tapering and discontinuing at least 2 weeks prior

  • Buspirone - potential risk of toxicity; consider tapering and discontinuing at least 5 days prior

C

  • Chlorpheniramine - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; consider tapering and discontinuing at least 2 weeks prior

  • Clomipramine - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; consider tapering and discontinuing at least 2 weeks prior

  • Citalopram - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; may increase ibogaine blood concentrations; consider tapering and discontinuing at least 2 weeks prior

D

  • Desipramine - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; consider tapering and discontinuing at least 2 weeks prior

  • Desvenlafaxine - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; consider tapering and discontinuing at least 2 weeks prior

  • Duloxetine - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; consider tapering and discontinuing at least 2 weeks prior

E

  • Escitalopram - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; may increase ibogaine blood concentrations; consider tapering and discontinuing at least 2 weeks prior

F

  • Fluoxetine - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; may increase ibogaine blood concentrations; consider tapering and discontinuing at least 6 weeks prior

  • Fluvoxamine - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; consider tapering and discontinuing at least 2 weeks prior

I

  • Imipramine - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; consider tapering and discontinuing at least 2 weeks prior

  • Isocarboxazid - potential risk of toxicity; consider tapering and discontinuing at least 10 days prior

L

  • Levomilnacipran - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; consider tapering and discontinuing at least 2 weeks prior

M

  • Mirtazapine - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; may increase ibogaine blood concentrations; consider tapering and discontinuing at least 2 weeks prior

  • Moclobemide - potential risk of toxicity; consider tapering and discontinuing at least 10 days prior

  • Methysergide - pretreatment resulted in an intensification of DMT subjective effects

N

  • Nortriptyline - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; consider tapering and discontinuing at least 2 weeks prior

P

  • Paroxetine - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; may increase ibogaine blood concentrations; consider tapering and discontinuing at least 2 weeks prior

  • Phenelzine - potential risk of toxicity; consider tapering and discontinuing at least 10 days prior

  • Pindolol - pretreatment enhanced DMT effects by 2-3 times; significant enhancement in 4-6 clinical clusters in the hallucinogen rating scale; mean arterial blood pressure effects were enhanced, heart rate responses were blunted, prolactin responses were reduced

S

  • Selegiline - potential risk of toxicity; consider tapering and discontinuing at least 10 days prior

  • Sertraline - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; may increase ibogaine blood concentrations; consider tapering and discontinuing at least 2 weeks prior

T

  • Tranylcypromine - potential risk of toxicity; consider tapering and discontinuing at least 10 days prior

  • Trazodone - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; consider tapering and discontinuing at least 1 week prior

V

  • Venlafaxine - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; may increase ibogaine blood concentrations; consider tapering and discontinuing at least 2 weeks prior

  • Vilazodone - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; consider tapering and discontinuing at least 2 weeks prior

  • Vortioxetine - risk of additive QTc interval prolongation, arrhythmias, or cardiotoxicity; consider tapering and discontinuing at least 2 weeks prior

LSD

DMT